MSD & Kyowa Question NICE’s Processes After English Funding Rejected For Rare Disease Drugs

MSD and Kyowa Kirin have separately criticized England’s HTA body, NICE, for assessing their respective rare disease medicines Welireg and Crysvita using its standard appraisal pathway. Both medicines were provisionally rejected for reimbursement.